NGF and Miyoshi myopathy: First, in 374 newly diagnosed MM patients enrolled in two clinical trials (GEM2012MENOS65 and GEM2014MAIN) who received first-line treatment based on bortezomib, lenalidomide and dexamethasone induction followed by autologous stem cell transplantation, consolidation and maintenance, CTPCs were detected by NGF in more than 90% of newly diagnosed MM patients [18].